New PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard…
Deltek Recognized for Its AI-Enabled PSA and ERP Applications
HERNDON, Va., March 12, 2026 /PRNewswire/ -- Deltek, the intelligent platform for…
